## LOGS Rec'M PCT/PTO 06 JUN 2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In ma annihoption of	Porthwick at al			
In re application of:	Borthwick, et al.			
International App. No.:	PCT/EP2003/013799	Group Art Unit:		
International Filing Date:	December 4, 2003	Examiner:		
For:	PYROLYDIN-2-ONE DERIVAT FACTOR XA	IVES AS INHIBITORS OF THROMBIN AND		
Commissioner for Patents Washington, D.C. 20231				
	INFORMATION DISCLO	SURE STATEMENT		
Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97				
<ul> <li>[ ] Copies of the references are enclosed</li> <li>[ ] Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))</li> <li>[X] A copy of the International Search Report which issued on International Application No. PCT/EP2003/013799 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.</li> <li>A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the</li> </ul>				
filing d applica occurs	ate of the above application or date	of entry into the national stage of an international first Office action on the merits, whichever event		
of a fir		ubmitted herewith is being filed before the mailing Request For Continued Examination under 37		
filing date o an internatio event occurr (1) a fi	f the above application or the date onal application or after the mailing red last, but <b>before</b> the mailing date inal action under § 1.113 or otice of allowance under § 1.311,	ted herewith is being filed after three months of the of entry into the national stage as set forth in § 1.491 of date of the first Office Action on the merits, whichever of either:		
Statement w		foreign patent office in a counterpart foreign the filing of this statement.		

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information

Disclosure Statement under § 1.97(c) (\$240.00).

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under §
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

John L. Lemanowicz Attorney for Appliant Registration No. 37,380

Date: 6/6/05 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8247 Facsimile: (919) 483-7988

10/537646

JC09 Rec'd PCT/PTO A SIGNAL 2005 **FORM PTO-1449** INFORMATION DISCLOSURE STATEMENT NO. PCT/EP2003/013799 PG5041USW **APPLICANT** Borthwick et al. **INTERNATIONAL GROUP FILING DATE** 12/4/03 **U.S. PATENT DOCUMENTS** Filing Date Examiner **Issue Date** Class Patent Name Subclass Appropriate Initials Number Continue on page FOREIGN PATENT DOCUMENTS Translation **Document** Publication Yes | No Number Date Class Country Subclass 99/62904 12/9/99 **PCT** PCT 93/01208 1/21/93 12/19/02 **PCT** 02/100886 02/100830 12/19/02 **PCT** 03/043981 5/30/03 **PCT** Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Continue on page DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the

applicant.